Axil Capital Advisors | Venture Capital

top of page

ENGLISH

日本語

Top

About

Team

Portfolio

Contact

Axil Capital is a venture capital firm based in Tokyo, Japan, specializing in biomedical & healthcare technology investments, with emphasis on supporting the growth of early-stage ventures by leveraging our global network and resources.

Axil Recent News (EN)

Axil Capital's Past News

Portfolio Recent News (EN)

Portfolio Companies' Recent News

Oct 1, 2024

United Immunity has published an academic paper on next-generation vaccines using a nanoparticle drug delivery system.

Sep 10, 2024

Jolly Good, in collaboration with Otsuka Pharmaceutical, has started providing VR to support dementia care.

Sep 10, 2024

Luca Science has published a paper in Nature Metabolism on the relief of Leigh syndrome.

Aug 7, 2024

GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia.

Jul 29, 2024

Techsomed Announces U.S. Launch of BioTraceIO Vision and BioTraceIO Precision Software for Image-Guided Ablation Therapy.

Jul 28, 2024

Allgenesis is on track for Phase 2 clinical trial with AG-80308 for dry eye disease.

Jul 26, 2024

United Immunity enters into the Research Collaboration Agreement with AstraZeneca.

Jul 25, 2024

Allgenesis is developing a treatment for diabetic macular edema.

Jul 22, 2024

HIROSAKI LI raised a total of 2.38 billion yen in a Series C round of financing.

Jul 1, 2024

Jolly Good partners with Persol Tempstaff to launch medical DX staffing services.

Jun 28, 2024

Perseus Proteomics announced the end of Ph I Clinical Trial for Polycythemia Vera.

Jun 24, 2024

The core technology patent for Cellusion's development products was granted in Japan.

Jun 3, 2024

Cranebio exhibited at the International Society of Food and Environmental Viruses.

May 9, 2024

Jolly Good partners with ExaMD, a Health and Medical AI Company.

Apr 12, 2024

Juran Kato, CEO of GEXVal gave a lecture at CPHI Japan 2024.

Apr 11, 2024

Cranebio has released a reagent kit that detects Escherichia coli by luminescence.

Apr 3, 2024

Otsuka Pharmaceutical and Jolly Good began offering a new Emotional Awareness Training VR program through their joint venture, FACEDUO, a virtual reality (VR) program.

Mar 25, 2024

A paper on corneal regenerative medicine, a joint research between Cellusion and Keio University, was published in the Keio Medical Journal.

Mar 18, 2024

United Immunity secures ￥180 million by Debt Financing from Aozora Corporate Investment.

Mar 5, 2024

Perseuse Proteomics has been adopted as Tokyo Dtrategic Innovation Promotion Program.

Mar 4, 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins.

Feb 22, 2024

Jolly Good Revolutionizes Healthcare with Immersive Service for Apple Vision Pro.

Jan 29, 2024

National Yangming Jiaotong University, a collaborative research partner of Elixiron Immunotherapeutics, published an article on fusion proteins for cancer treatment.

Jan 8, 2024

Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation.

Portfolio Companies' Past News

【 Head Office 】

Nittochi Nishi-shinbashi Bldg. 7F
1-11-4 Nishi-shinbashi Minato-ku, Tokyo 105-0003, Japan

【 Technology & Innovation Center 】

GLOBAL LIFESCIENCE HUB, Nihombashi Muromachi Mitsui Tower 7F
3-2 Nihombashi Muromachi, Chuo-ku, Tokyo 103-0022

© Axil Capital All Rights Reserved

bottom of page